LDS/Medical Tests/Vasoactive Intestinal Polypeptide (VIP)

Vasoactive Intestinal Polypeptide (VIP)

Vasoactive intestinal polypeptide (VIP) is a 28–amino acid neuropeptide that functions both as a neurotransmitter and a neuroendocrine hormone. It is synthesized primarily in the enteric nervous system, pancreas, hypothalamus, and peripheral autonomic neurons, initially as a preprohormone that undergoes post-translational modification to produce active VIP. Stored in secretory vesicles, VIP is released via calcium-dependent exocytosis.

VIP exerts diverse physiological effects across multiple systems. In the gastrointestinal tract, it stimulates intestinal water and electrolyte secretion, promotes pancreatic bicarbonate and enzyme release, inhibits gastric acid secretion, and relaxes gastrointestinal smooth muscle. Within the cardiovascular system, VIP is a potent vasodilator, contributing to decreased systemic vascular resistance and blood pressure regulation. In the nervous system, it acts as a neuromodulator and neurotransmitter, influencing circadian rhythm regulation, synaptic plasticity, and autonomic control. Additionally, VIP has emerging roles in immune modulation, with evidence supporting anti-inflammatory properties.

Pathologically, markedly elevated VIP levels are most often seen in VIP-secreting tumors (VIPomas), of which more than 90% originate in the pancreas. These tumors typically present with the classical syndrome of watery diarrhea, hypokalemia, and achlorhydria (WDHA syndrome). Neuroblastomas and other rare neuroendocrine tumors may also produce VIP. Beyond tumors, alterations in VIP signaling have been linked to asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease, autonomic dysfunction, neurodegenerative disorders such as Parkinson’s and Alzheimer’s disease, and circadian rhythm disturbances. While routine measurement is largely focused on tumor diagnosis, research continues to explore broader biomarker applications of VIP.

  • Evaluation of patients with suspected VIPomas or pancreatic neuroendocrine tumor presenting chronic watery diarrhea
  • Assessment of neuroblastomas, particularly in conjunction with catecholamine metabolites (HVA, VMA)
  • Aid in the diagnostic workup of unexplained achlorhydric diarrhea
  • Potential adjunct marker in research contexts for autonomic, inflammatory, or neurodegenerative disorders

Increased in:

  • VIPoma (pancreatic neuroendocrine tumor)
  • Neuroblastoma
  • Pancreatic neuroendocrine tumors

Decreased in:

  • Asthma and COPD (deficient VIP-mediated bronchodilation and anti-inflammatory action)
  • Autonomic neuropathies
  • Neurodegenerative diseases (impaired VIP neuronal regulation)
  • Circadian rhythm disturbances

<86 pg/mL

Chemiluminescent immunoassay, enzyme immunoassay, enzyme-linked immunosorbent assay (ELISA).

Serum, SST tube.

Stability

  • Ambient: 4 hrs.
  • Refrigerated: 24 hrs.
  • Frozen: 3 months
Homovanillic acid, Vanillylmandelic acid, comprehensive metabolic panel, catecholamines, serum electrolytes, metanephrines, cortisol, CBC, PHOX gene mutation analysis, ACTH.
2 to 4 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login